Literature DB >> 8527732

Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease.

G A Qureshi1, S Baig, I Bednar, P Södersten, G Forsberg, A Siden.   

Abstract

The concentration of nitrite, a metabolite of nitric oxide (NO), was increased in the cerebrospinal fluid (CSF) of untreated patients with Parkinson's disease and in patients treated with L-DOPA in comparison with a group of patients without dopaminergic dysfunction. There was no difference in the concentration of L-arginine (ARG), a precursor of NO, between the groups. There was a highly significant, linear relationship between the concentration of nitrite and ARG in the CSF suggesting that the production of NO is dependent on the availability of ARG. The results support the possibility that production of NO is increased in the brain in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527732     DOI: 10.1097/00001756-199508000-00013

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  31 in total

1.  Testing NF-κB-based therapy in hemiparkinsonian monkeys.

Authors:  Susanta Mondal; Avik Roy; Arundhati Jana; Sankar Ghosh; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-03       Impact factor: 4.147

2.  Protection of dopaminergic neurons in a mouse model of Parkinson's disease by a physically-modified saline containing charge-stabilized nanobubbles.

Authors:  Saurabh Khasnavis; Avik Roy; Supurna Ghosh; Richard Watson; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2014-03       Impact factor: 4.147

3.  No changes in cerebrospinal fluid levels of nitrite, nitrate and cyclic GMP with aging. Short communication.

Authors:  K Yamada; K Nishiwaki; K Hattori; K Senzaki; M Nagata; T Komatsu; Y Shimada; T Nabeshima
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys.

Authors:  Susanta Mondal; Suresh B Rangasamy; Avik Roy; Sridevi Dasarathy; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Immunol       Date:  2019-05-01       Impact factor: 5.422

5.  AETIQ: a novel synthetic compound with anti-inflammatory properties in activated microglia.

Authors:  Hyo Jin Son; Nari Shin; Eun Jung Shin; Dae Yoon Chi; Jai Woong Seo; Cheol Soon Lee; Onyou Hwang
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 6.  Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.

Authors:  Li Qian; Patrick M Flood; Jau-Shyong Hong
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

Review 7.  The role of nitric oxide in neurodegeneration. Potential for pharmacological intervention.

Authors:  J A Molina; F J Jiménez-Jiménez; M Ortí-Pareja; J A Navarro
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

Review 8.  Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms.

Authors:  Richard H Foxton; John M Land; Simon J R Heales
Journal:  Neurochem Res       Date:  2006-12-27       Impact factor: 3.996

9.  FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

Authors:  S Hunot; N Dugas; B Faucheux; A Hartmann; M Tardieu; P Debré; Y Agid; B Dugas; E C Hirsch
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

Review 10.  The role of astroglia on the survival of dopamine neurons.

Authors:  María Angeles Mena; Sonsoles de Bernardo; Maria José Casarejos; Santiago Canals; Eulalia Rodríguez-Martín
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.